SMSanjay Mohan
Sanjay Mohan
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sanjay Mohan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ashwin Kishtagari
Vanderbilt University Medical Center, Division of Hematology/Oncology
2 shared publications - Kateryna Fedorov
Vanderbilt University Medical Center, Division of Hematology/Oncology
2 shared publications - Somedeb Ball
Vanderbilt University Medical Center, Internal Medicine, Division of Hematology and Oncology
2 shared publications - Callee Brooks
Vanderbilt University Medical Center
1 shared publication - David A. Sallman
Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
1 shared publication - Emily F. Mason
Vanderbilt University Medical Center
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Outcomes with Hypomethylating Agent and Venetoclax Combination in Patients with TP53-mutated Myelodysplastic Syndromes
From the 2026 National Summit on Hematologic Cancers
- 28 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Open AccessOutcomes with Hypomethylating Agent and Venetoclax Combination in Patients with TP53-mutated Myelodysplastic Syndromes
From the 2026 National Summit on Hematologic Cancers
- Open Access
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Context-Dependent Prognostic Significance of RAS Mutations in AML and Implications for Treatment Strategy
From the 2026 National Summit on Hematologic Cancers
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Open AccessContext-Dependent Prognostic Significance of RAS Mutations in AML and Implications for Treatment Strategy
From the 2026 National Summit on Hematologic Cancers